As the US sits firmly in the middle of peak flu season, a report published in Morbidity and Mortality Weekly Report found that this season's flu vaccine is only 23% effective at preventing the virus.
As the US sits firmly in the middle of peak flu season, a report published in Morbidity and Mortality Weekly Report (MMWR) found that this season’s flu vaccine is only 23% effective at preventing the virus.
Estimates for the effectiveness of the flu vaccine have ranged from 10% to 60% since the CDC began conducting annual studies in 2004-2005.
“Although influenza vaccines are the best tool for prevention of influenza currently available, more effective vaccines are needed,” the authors wrote.
Approximately 70% of this season’s viruses have drifted from the vaccine virus, which accounts for the reduced vaccine effectiveness. However, even when there are drifted viruses the CDC continues to recommend influenza vaccination because the vaccine still prevents some infections as well as serious complications.
“Physicians should be aware that all hospitalized patients and all outpatients at high risk for serious complications should be treated as soon as possible with one of three available influenza antiviral medications if influenza is suspected, regardless of a patient’s vaccination status and without waiting for confirmatory testing,” Joe Bresee, branch chief in CDC’s Influenza Division, said in a statement. “Healthcare providers should advise patients at high risk to call promptly if they get symptoms of influenza.”
In light of the low effectiveness of the vaccine, additional influenza prevention and treatment measures are important, especially for those high at risk for serious flu complications, according to the authors of the MMWR report. They added that practices that can help decrease the spread of the disease include respiratory hygiene, cough etiquette, social distancing by staying home when ill, and hand washing.
Antiviral medications should be recommended for patients regardless of whether or not they have been vaccinated as the treatment can reduce the duration of the illness and reduce complications. However, while there is no national shortage of antiviral medications
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Understanding How Fitness Affects Digestive Diseases
April 18th 2025Exercise is a powerful modulator of gut health in patients with gastrointestinal (GI) conditions, as moderate activity can ease gut inflammation, reduce colorectal cancer risk, and relieve constipation, while intense workouts may backfire, causing reflux, GI bleeding, or gut barrier disruption.
Read More
FDA Greenlights Dupilumab for Chronic Spontaneous Urticaria, Marking First Approval in a Decade
April 18th 2025Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives and itching remain uncontrolled by antihistamines.
Read More